ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO695

Synergetic B-Cell Immunomodulation with Rituximab and Belimumab Combination Treatment in Severe, Refractory SLE: The SynBiose Proof-of-Concept Study

Session Information

Category: Glomerular

  • 1001 Glomerular: Basic/Experimental Immunology and Inflammation

Authors

  • Kraaij, Tineke, Leiden University Medical Center, Leiden, Netherlands
  • Kamerling, Sylvia, Leiden University Medical Center, Leiden, Netherlands
  • de Rooij, Esther, Leiden University Medical Center, Leiden, Netherlands
  • Van daele, Paul L.a., Erasmus MC, Rotterdam, Netherlands
  • Bredewold, Edwin, Leiden University Medical Center, Leiden, Netherlands
  • Bakker, Jaap A., Leiden University Medical Center, Leiden, Netherlands
  • Bajema, Ingeborg M., Leiden University Medical Center, Leiden, Netherlands
  • Scherer, Hans Ulrich, Leiden University Medical Center, Leiden, Netherlands
  • Toes, Rene, Leiden University Medical Center, Leiden, Netherlands
  • Huizinga, Tom, Leiden University Medical Center, Leiden, Netherlands
  • Rabelink, Ton J., Leiden University Medical Center, Leiden, Netherlands
  • van Kooten, Cees, Leiden University Medical Center, Leiden, Netherlands
  • Teng, Yoe Kie Onno, Leiden University Medical Center, Leiden, Netherlands
Background

Neutrophil extracellular traps (NETs) are auto-antigenic DNA strands and could give rise to SLE-specific autoantibodies that can deposit in glomeruli. It has been shown that autoantibodies can induce NETs, contributing to a vicious circle of immune activation in SLE. We hypothesized that eliminating autoantibodies can lead to decreased NET induction and thereby ameliorating disease in SLE. We designed a proof-of-concept study to eliminate autoantibodies and NET formation through synergetic B-cell immunomodulation with rituximab and belimumab (RTX+BLM) in severe refractory SLE.

Methods

We treated patients with severe, refractory SLE in a phase 2 study with RTX+BLM. The primary endpoint assessed reduction of pathogenic autoantibodies and NET induction at week 24. Anti-dsDNA autoantibodies were measured and high sensitivity FACS was performed to assess B-cell subsets. NET induction was measured with 3D confocal microscopy.

Results

We included 14 patients with severe, refractory SLE of whom 11 had a renal flare. At 24 weeks we observed significant reductions in anti-dsDNA autoantibodies (p=0.0015). CD19+ B-cells were depleted throughout the study (p=0.0005) while plasma cells (PCs) temporarily decreased but returned at week 24 despite persistent depletion of transitional B-cells. Taken together with reductions of autoantibodies and stable total IgG, there is no reconstitution of autoreactive PCs. We observed significant decrease in NET reduction (p=0.0017). In vitro studies elucidated this resulted in reduction of immune complexes by RTX+BLM. Importantly, beneficial immunological effects translated to amelioration of clinical disease activity: SLEDAI decreased from a median of 18 to 2 (p=0.0002). Ten out of 11 LN patients showed a response (4 complete renal responders). The response was achieved while tapering immunosuppressive drugs. Treatment was well-tolerated.

Conclusion

The SynBiose study is the first to demonstrate that RTX+BLM ameliorated disease in severe SLE in association with the reduction of pathogenic autoantibodies and immune complex-mediated NET induction. Therefore, RTX+BLM represents a novel treatment concept in SLE. ClinicalTrials.gov NCT02284984